CoChat
Sign Up
Cited by 25Thyroid Cancer Diagnosis and TreatmentNeuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Glucagon-Like Peptide-1 Receptor Imaging with [Lys 40 (Ahx-HYNIC- 99 m Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report

Open access
Pach, D., Sowa-Staszczak, A., Jabrocka-Hybel, A., Stefańska, A., Tomaszuk, M., Mikołajczak, R., Janota, B., Trofimiuk-Müldner, M. +2 more·2013·International Journal of Endocrinology
DOI 10.1155/2013/384508PMC PMC3626320
Open this paper in CoChat — free accountOpen PDF

Abstract

Introduction . Epidemiological studies on medullary thyroid cancer (MTC) have shown that neither a change in stage at diagnosis nor improvement in survival has occurred during the past 30 years. In patients with detectable serum calcitonin and no clinically apparent disease, a careful search for local recurrence, and nodal or distant metastases, should be performed. Conventional imaging modalities will not show any disease until basal serum calcitonin is at least 150 pg/mL. The objective of the study was to present the first experience with labelled glucagon-like peptide-1 (GLP-1) analogue [Lys 40 (Ahx-HYNIC- 99m Tc/EDDA)NH 2 ]-exendin-4 in the visualisation of MTC in humans. Material and Method . Four patients aged 22–74 years (two with sporadic and two with MEN2 syndrome-related disseminated MTC) were enrolled in the study. In all patients, GLP-1 receptor imaging was performed. Results . High-quality images were obtained in all patients. All previously known MTC lesions have been confirmed in GLP-1 scintigraphy. Moreover, one additional liver lesion was detected in sporadic MTC male patient. Conclusions . GLP-1 receptor imaging with [Lys 40 (Ahx-HYNIC- 99m Tc/EDDA)NH 2 ]-exendin-4 is able to detect MTC lesions. GLP-1 scintigraphy can serve as a confirmatory test in MTC patients, in whom other imaging procedures are inconsistent.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2013/384508

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Most human medullary thyroid carcinomas and hyperplastic C cells express GLP-1R.

    “most human medullary thyroid carcinomas and hyperplastic C cells express GLP-1R (75, 77) (Figure 2).”

    From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [77]

    The Discussion reports GLP-1R expression in 28% of medullary thyroid carcinomas examined, contrary to the claim that most express it. It also says many calcitonin-positive C cells were GLP-1R-negative; the copy does not establish expression in most hyperplastic C cells. No page number is provided in our copy. (LLM, conf=0.89)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 33 · Cited by 25

Research works printed but not linked: 33

  1. [1]Sippel RS Kunnimalaiyaan M Chen H Current management of medullary thyroid cancer Oncologist 2008 13 5 539 547 2-s2.0-45749139320 18515739
  2. [2]Ball DW Medullary thyroid cancer: monitoring and therapy Endocrinology and Metabolism Clinics of North America 2007 36 3 823 837 17673130 PMC2806819
  3. [3]Ball DW Medullary thyroid cancer: therapeutic targets and molecular markers Current Opinion in Oncology 2007 19 1 18 23 2-s2.0-33845356681 17133107
  4. [4]Machens A Ukkat J Hauptmann S Dralle H Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis Archives of Surgery 2007 142 3 289 293 2-s2.0-33947371271 17372055
  5. [5]Moley JF Lairmore TC Phay JE Hereditary endocrinopathies Current Problems in Surgery 1999 36 9 653 762 2-s2.0-0033191023 10491659
  6. [6]Kebebew E Kikuchi S Duh Q-Y Clark OH Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer Archives of Surgery 2000 135 8 895 901 2-s2.0-0033868467 10922248
  7. [7]Pacini F Castagna MG Cipri C Schlumberger M Medullary thyroid carcinoma Clinical Oncology 2010 22 6 475 485 2-s2.0-77954757206 20627492
  8. [8]American Thyroid Association Guidelines Task Force Kloos RT Eng C Medullary thyroid cancer: management guidelines of the American Thyroid Association Thyroid 2009 19 6 565 612 2-s2.0-67749130797 19469690
  9. [9]Elisei R Cosci B Romei C Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study Journal of Clinical Endocrinology and Metabolism 2008 93 3 682 687 2-s2.0-40849094269 18073307
  10. [10]Scollo C Baudin E Travagli JP Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer Journal of Clinical Endocrinology and Metabolism 2003 88 5 2070 2075 2-s2.0-0038369070 12727956
  11. [11]Machens A Schneyer U Holzhausen HJ Dralle H Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level Journal of Clinical Endocrinology and Metabolism 2005 90 4 2029 2034 2-s2.0-17844400055 15634717
  12. [12]Giraudet AL Al Ghulzan A Aupérin A Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times European Journal of Endocrinology 2008 158 2 239 246 2-s2.0-38949129191 18230832
  13. [13]Reubi JC Waser B Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting European Journal of Nuclear Medicine and Molecular Imaging 2003 30 5 781 793 2-s2.0-0037907532 12707737
  14. [14]Wild D Mäcke H Christ E Gloor B Reubi JC Glucagon-like peptide 1-receptor scans to localize occult insulinomas The New England Journal of Medicine 2008 359 7 766 768 2-s2.0-49449085799 18703486
  15. [15]Christ E Wild D Forrer F Glucagon-like peptide-1 receptor imaging for localization of insulinomas Journal of Clinical Endocrinology and Metabolism 2009 94 11 4398 4405 2-s2.0-70449111654 19820010
  16. [16]Wild D Wicki A Mansi R Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT Journal of Nuclear Medicine 2010 51 7 1059 1067 2-s2.0-77954986457 20595511
  17. [17]Tai D Poon D Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers Journal of Oncology 2010 2010 7 pages 2-s2.0-77957947626 398564 PMC2938455 20862373
  18. [18]Rufini V Salvatori M Garganese MC Di Giuda D Lodovica Maussier M Troncone L Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma Rays 2000 25 2 273 282 2-s2.0-0034173478 11370545
  19. [19]Pinchot SN Kunnimalaiyaan M Sippel RS Chen H Medullary thyroid carcinoma: targeted therapies and future directions Journal of Oncology 2009 2009 7 pages 2-s2.0-75449097942 183031 PMC2798103 20069043
  20. [20]Santarpia L Ye L Gagel RF Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma Journal of Internal Medicine 2009 266 1 99 113 2-s2.0-66849128386 19522829
  21. [21]Shahram D [99mTc-DMSA (V)] in detection of metastases of medullary thyroid carcinoma Iranian Journal of Nuclear Medicine 2006 14 26 15 24 2-s2.0-33846796073
  22. [22]Haugen BR Lin EC Isotope imaging for metastatic thyroid cancer Endocrinology Metabolism Clinics of North America 2001 30 469 492 11444171
  23. [23]Uğur Ö Kostakoğlu L Güler N Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid European Journal of Nuclear Medicine 1996 23 10 1367 1371 2-s2.0-0029665302 8781142
  24. [24]Rufini V Salvatori M Garganese MC Di Giuda D Lodovica Maussier M Troncone L Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma Rays 2000 25 2 273 282 2-s2.0-0034173478 11370545
  25. [25]Guilloteau D Baulieu JL Besnard JC Medullary-thyroid-carcinoma imaging in an animal model: use of radiolabeled anticalcitonin F(ab')2 and meta-iodobenzylguanidine European Journal of Nuclear Medicine 1985 11 6-7 198 200 2-s2.0-0022343365 4076227
  26. [27]Kaltsas G Korbonits M Heintz E Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors Journal of Clinical Endocrinology and Metabolism 2001 86 2 895 902 2-s2.0-17744373472 11158063
  27. [28]Arslan N Ilgan S Yuksel D Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery Clinical Nuclear Medicine 2001 26 8 683 688 2-s2.0-0034919634 11452174
  28. [29]Szakáll S Ésik O Bajzik G 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma Journal of Nuclear Medicine 2002 43 1 66 71 2-s2.0-0036007410 11801705
  29. [30]Gotthardt M Battmann A Höffken H 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature Nuclear Medicine Communications 2004 25 5 439 443 2-s2.0-16544377183 15100501
  30. [31]Ong SC Schöder H Patel SG Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels Journal of Nuclear Medicine 2007 48 4 501 507 2-s2.0-34248594179 17401085
  31. [32]Beheshti M Pöcher S Vali R The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT European Radiology 2009 19 6 1425 1434 19156423
  32. [33]Hoegerle S Altehoefer C Ghanem N Brink I Moser E Nitzsche E 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels European Journal of Nuclear Medicine 2001 28 1 64 71 2-s2.0-0034746433 11202454
  33. [34]Körner M Stöckli M Waser B GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting Journal of Nuclear Medicine 2007 48 736 743 17475961

Authors
Pach, D., Sowa-Staszczak, A., Jabrocka-Hybel, A., Stefańska, A., Tomaszuk, M., Mikołajczak, R., Janota, B., Trofimiuk-Müldner, M., Przybylik-Mazurek, E., & Hubalewska-Dydejczyk, A.
Affiliations
  • Jagiellonian University (PL)
  • Department of Endocrinology, Jagiellonian University Medical College, Kopernika 17, 31-501 Krakow, Poland
  • National Centre for Nuclear Research (PL)
ORCID
Venue
International Journal of Endocrinology
Publisher
Wiley
Published
2013
Volume
2013
Pages
1-6
ISSN
  • 1687-8337 (ISSN-L)
  • 1687-8345
DOI
10.1155/2013/384508
PMC
PMC3626320
OpenAlex
W1988150020
Cited by
25
References
33
Citations by year
2026: 1 · 2023: 1 · 2022: 4 · 2021: 2 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 6 · 2016: 1 · 2015: 2 · 2014: 2
FWCI
1.31
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Endocrinology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
  • Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
  • Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords
medullary thyroid carcinoma, exendin-4, 99mTc scintigraphy, local recurrence detection, metastasis detection, calcitonin, liver metastasis, tumor imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review